pointbiopharma(PNT) - 2023 Q3 - Quarterly Report

Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from ______to ______. Commission file number: 001-39311 POINT BIOPHARMA GLOBAL INC. (Exact name of registrant as specified in its charter) (State or oth ...